E Fund Management Co., Ltd.
- SEC CIK
- 0001842296
- Latest filing
- Aug 10, 2026
HALO holding history
Halozyme Therapeutics, Inc. in every 13F filed by E Fund Management Co., Ltd., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
HALO overviewAll 13F holders of HALOFull Q2 2026 holdings
- Shares (Q2 2026)
- 5,810
- Value
- $454.7K
- % of portfolio
- <0.1%
- Quarters held
- 17
- Since Q4 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 5,810 | $454.7K | <0.1% | −2,933−33.5% | Reduced | Holders |
| Q1 2026 | 8,743 | $565.1K | <0.1% | – | No prior filing | Holders |
| Q3 2025 | – | – | – | – | Not filed | Holders |
| Q2 2025 | 19,926 | $1.04M | <0.1% | +9,542+91.9% | Added | Holders |
| Q1 2025 | 10,384 | $662.6K | <0.1% | −5,002−32.5% | Reduced | Holders |
| Q4 2024 | 15,386 | $735.6K | <0.1% | +3,477+29.2% | Added | Holders |
| Q3 2024 | 11,909 | $681.7K | <0.1% | +3,955+49.7% | Added | Holders |
| Q2 2024 | 7,954 | $416.5K | <0.1% | −2,431−23.4% | Reduced | Holders |
| Q1 2024 | 10,385 | $422.5K | <0.1% | −1,638−13.6% | Reduced | Holders |
| Q4 2023 | 12,023 | $444.4K | <0.1% | +149+1.3% | Added | Holders |
| Q3 2023 | 11,874 | $454.0K | <0.1% | −1,278−9.7% | Reduced | Holders |
| Q2 2023 | 13,152 | $474.0K | <0.1% | +3,875+41.8% | Added | Holders |
| Q1 2023 | 9,277 | $354.0K | <0.1% | +1,850+24.9% | Added | Holders |
| Q4 2022 | 7,427 | $423.0K | <0.1% | −4,078−35.4% | Reduced | Holders |
| Q3 2022 | 11,505 | $455.0K | <0.1% | +1,505+15.0% | Added | Holders |
| Q2 2022 | 10,000 | $440.0K | <0.1% | +2,274+29.4% | Added | Holders |
| Q1 2022 | 7,726 | $308.0K | <0.1% | +2,699+53.7% | Added | Holders |
| Q4 2021 | 5,027 | $202.0K | <0.1% | +5,027 | New | Holders |